anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mutations in the isocitrate dehydrogenase (IDH) gene are recognized as the key drivers in the oncogenesis of astrocytoma and oligodendroglioma. However, the significance of IDH mutation in tumor maintenance and malignant transformation has not been elucidated. We encountered a unique case of IDH-mutant astrocytoma that, upon malignant transformation, presented two distinct intratumoral components: one IDH-wildtype and one IDH-mutant. The IDH-wild-type component exhibited histological findings similar to those of small cell-type glioblastoma with a higher Ki-67 index than the IDH-mutant component. Despite their genetic divergence, both components exhibited similar comprehensive methylation profiles within the CpG island and were classified into methylation class of "Astrocytoma, IDH-mutant; High Grade" by the German Cancer Center (DKFZ) classifier v11.4. Phylogenetic analysis demonstrated that the IDH-wildtype component emerged as a subclonal component of the primary tumor. Detailed molecular analyses revealed that the loss of the IDH mutation was induced by the hemizygous loss of the entire arm of chromosome 2, on which IDH1 gene is located. Notably, the IDH-wild-type subclones uniquely acquired CDKN2A/B homozygous deletion and PDGFRA amplification, which is a marker of the aggressive phenotype of astrocytoma, IDH-mutant. Because these genetic abnormalities can drive oncogenic pathways, such as the PI3K/AKT/mTOR and RB signaling pathway, IDH-mutant gliomas that acquired these mutations were no longer dependent on the initial driver mutation, the IDH mutation. Molecular analysis of this unique case provides insight that in a subset of astrocytoma, IDH-mutant that acquired these genetic abnormalities, IDH mutation may not play a pivotal role in tumor growth and acquisition of these genetic abnormalities may contribute to the acquisition of resistance to IDH inhibitors.
The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will use optimal medication just like the RSD+Medicine group. Third we will conduct a clinic and a telephone follow-up(Total 36 months).
PCT No. PCT/EP95/01778 Sec. 371 Date Nov. 10, 1997 Sec. 102(e) Date Nov. 10, 1997 PCT Filed May 11, 1995 PCT Pub. No. WO96/35782 PCT Pub. Date Nov. 14, 1996The invention relates to a nucleotide sequence, which is able to inhibit the IL-6 activity, its use in therapy as well as pharmaceutical compositions containing it. In particular, it relates to a nucleotide sequence which comprises: i) at least one nucleotide sequence that is an APRE element of general formula ZXMYKGKAA, wherein Z represents T or G or can also be absent, X represents T or can also be absent, M represents C or A, Y represents C or T and K represents T or G, in conjunction with ii) at least one nucleotide sequence constituting a transcription factor binding site other than the APRE element, such as those present in promoter regions.
Stable anaesthetic solutions for injection which are free from the secondary toxic effects due to the use of adrenalin in the usual preparations are prepared by using 3 : 4-dihydroxyphenylethanolamine as the vaso-constricting agent. According to an example the aqueous solution contains hydrochloride of para-aminobenzoyl-diethylamino-ethanol, sodium chloride, potassium sulphate, and hydrochloride of 3 : 4-dihydroxy-phenylethanolamine. Acetone bisulphite may also be added.  Specification 439,168 is referred to.  The Specification as open to inspection under Sect. 91 contains additional examples relating to solutions containing (1) hydrochloride of para-butylamino-benzoyl-dimethylamino-ethanol, sodium chloride and the vaso-constrictor, and (2) para-amino-benzoyl-dimethylamino-methyl-butanol, sodium chloride and the vaso-constrictor.  This subject-matter does not appear in the Specification as accepted.
The invention discloses a strain Providence and the application in preparation antibacterials thereof. Providence (providencia? does is vermicola) No. 22, its deposit number CCTCC? No.M2013696. Providence of the present invention has antagonism No. 22, therefore can be by No. 22, Providence of the present invention for the preparation of in prevention and control vibrio alginolyticus or vibrio parahaemolytious preparation, this prevention and control vibrio alginolyticus or vibrio parahaemolytious preparation can be used as the effective microorganism preparation of instead of chemical medicine, be used for improving water quality, remove vibrio alginolyticus or vibrio parahaemolytious in aquaculture system, thereby prevention vibrio alginolyticus or the harm of vibrio parahaemolytious to aquaculture object, promote the development of culture fishery; Avoid aquatic products to carry vibrio alginolyticus or vibrio parahaemolytious, ensure human health safety.
In the intervention, VR will be employed to simulate a daily living environment familiar to older people. Participants will wear a commercially available head-mounted VR system with hand-held controllers to experience the participation of daily activities in a virtual environment. Simultaneous physical and cognitive training will be embedded in the training system to promote optimal function. Participants will attend physical training in a sitting position through cycling on an ergometer and moving the hand-held controllers. Motion sensors built into the VR system and ergometer will track these movements to control everyday tasks in the virtual environment (e.g., moving around the city). Simultaneously, participants will undergo cognitive training by participating in various tasks demanding cognitive functions, such as visual-spatial (e.g., wayfinding) and problem-solving (e.g., wallet loss) functions. Gamification will be employed to promote the motivation to participate. All training activities will be gamified by blending in fun elements, such as difficulty-levelling, competition, and e-tokens. Co-participation is allowed to promote interpersonal interactions. The prototype enables real-time co-viewing among participants. Other elderly centre members and the activity facilitators can share the view of the participants in the game on either a large-screen monitor or a tablet computer. They can simultaneously talk about and share their gaming experiences.
Pregnancy Category D   
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue losartan as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.  
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin­ angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue losartan potassium, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to losartan potassium for hypotension, oliguria, and hyperkalemia [see Use in Specific Populations (8.4)].   
Losartan potassium has been shown to produce adverse effects in rat fetuses and neonates, including decreased body weight, delayed physical and behavioral development, mortality and renal toxicity. With the exception of neonatal weight gain (which was affected at doses as low as 10 mg/kg/day), doses associated with these effects exceeded 25 mg/kg/day (approximately three times the maximum recommended human dose of 100 mg on a mg/m2 basis). These findings are attributed to drug exposure in late gestation and during lactation. Significant levels of losartan and its active metabolite were shown to be present in rat fetal plasma during late gestation and in rat milk.
'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance (1-4). Up to 20% of individuals in the general population acquire mutations in their bone marrow stem cells as they age that give that population of cells a survival or 'clonal' advantage for growth. The frequency of CHIP may be higher in patients with other cancers. CHIP increases with age, and has been shown to be a risk factor associated with cardiovascular disease and a tendency to the development of bone marrow cancers at a rate of 1% per year (1,2,5). CHIP is also associated with the development of bone marrow cancers that occur after chemotherapy. The investigators want to investigate whether CHIP is also a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions. They are also interested in determining if CHIP may explain why some patients do not recover normal blood counts after chemotherapy finishes.

The results from this study may help physicians better understand why some people have difficulty with chemotherapy (in the short and long-term) while others do not. Screening for CHIP in older patients may become a recommended standard that allows physicians to tailor anti-cancer treatment to the patient.
As the number of patients from diverse cultures increases in psychotherapeutic care, cross-cultural competencies of therapists become increasingly important. In particular, mental health care of patients with immigration background needs to be improved as studies show that these patients drop out of treatment more often and benefit less from therapy. In addition, patients with immigration background and refugees show higher prevalences in mental illnesses. Nevertheless, evaluated training programs to improve cross-cultural competencies in psychotherapists are lacking. In particular, web-based training programs, which allow therapists to work time-flexible and at their own pace on a training, are, to date, missing completely.

For the current study, a web-based training program to improve therapists' cross-cultural competencies was developed. It is based on existing conceptions of cross-cultural competencies. The developed program consists of six modules with the following contents: definitions and conceptions of culture, the role of cross-cultural competencies in psychotherapy, the influence of prejudices and discrimination as well as the role of migration and acculturation, and culturally sensitive diagnostics. The modules contain PDF-files with text-based information, video files, case studies with associated questions as well as practical exercises. The main focus of the training is the participants' self-reflection concerning their conceptions of (their own) culture and their beliefs about culturally diverse patients. The training group will be compared to two other groups, i.e. an education only and a waitlist control group. Whereas the waitlist control group will not receive any training materials, the education only group will receive a slimmed down version of the training consisting only of text-based information files.
At the Centre for Addiction and Mental Health (CAMH), the investigators will recruit a consecutive series of 186 participants aged 16 to 29 referred by the CAMH ED and related acute services to CAMH's EPI program for a pragmatic randomized controlled trial of a 2-way SMS intervention involving reminders, psychoeducation, and check-ins. The primary outcome will be rate of attendance at the first consultation appointment assessed through chart reviews. Secondary outcomes will include indicators of long-term service engagement as well as symptoms and functioning 6 months following study enrollment and health service utilization for up to 2 years using administrative data from the Institute for Clinical Evaluative Sciences (ICES). Administrative data will be used for an economic analysis. Participants who receive the active intervention will be asked to complete a web-based survey evaluating their experience and a subgroup will be asked to participate in in-depth in-person qualitative interviews. Patients and family members with lived experience will be engaged in all aspects of the project, including shaping the intervention and study design.

The investigators hypothesize that the intervention will result in increased rate of attendance at the first EPI consultation appointment, as well as improved longer-term engagement in outpatient EPI services compared to the sham comparator. Demonstrating evidence that this low-cost, low-complexity, youth-friendly intervention improves engagement in outpatient EPI services has the potential to improve long-term outcomes for young people with psychosis.
Tetanus diptheria toxoid (Td) (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1.5 and 2 hours depending on the needs of the participant.
The invention belongs to the field of articles in daily use and specifically relates to desert algae radiation-proof ingredient extraction, natural medical whitening ingredient extraction and a preparation method of beauty products such as Sunscreen cream, day cream and the like with the application of the ingredients. According to the invention, beauty products such as Sunscreen cream, day cream and the like are prepared by the adoption of a desert algae radiation-proof ingredient, skin whitening ingredients of rare Chinese herbal medicines such as Radix Astragali and Chinese angelica and raw materials of vitamin E, fragrance and the like. According to the invention, the desert algae mycosporine amino acids and scytonemin with a superpower anti-ultraviolet radiation effect and the skin whitening ingredients of Radix Astragali and Chinese angelica which have a good function of inhibiting tyrosinase activity are simultaneously applied. The two parts can be used together to have good radiation-proof and skin whitening effects. In addition, with the combination of the fragrance extracted from camphor, rose, white orchid, jasmine and mangnolia, beauty products with different sweet smells can be prepared. The beauty products are not irritative to skin when in use, and skin feels comfortable and soft without greasy feeling after the beauty products are used. In addition, the preparation method is simple and easy to operate and has a very wide market prospect.
The invention refers to mono- and divalent (diabody) single chain Fv (scFv) antibody fragments, obtained by recombinant DNA techniques from the anti-carcinoembryonic antigen (CEA) monoclonal antibody (Mab) CB/ior-CEA.1. This antibody has high affinity for CEA and is employed in the diagnosis and follow-up of human colorectal tumors. As the original Mab, the monovalent fragment and the diabody exhibit high affinity for human CEA and recognize an epitope dependent of carbohydrate conservation. The monovalent scFv fragment and the diabody have affinity constants for CEA of (5.0±0.4)×10 9  L mol −1  and (2.8±0.3)×10 10  L mol −1 , respectively. These two fragments do not show cross reactivity with human normal cells and tissues, exception made of the normal colonic mucosa, where CEA is occasionally present. The fragments can be produced through the expression in recombinant microorganisms, starting from the cloning of the encoding variable region nucleic acid sequences obtained from the hybridoma that produces Mab CB/ior-CEA.1. As the original Mab, the monovalent scFv and the diabody have the ability to identify in vivo cells that produce human CEA and grow as tumors in mice. The monovalent scFv and the diabody have a molecular size 5 and 2.5 times lower, respectively, than the mouse Mab, and do not have Fc domains, fact this that confers them the potential to better penetrate tissues in vivo and to be less immunogenic in man.
BACKGROUND: Anti-reflux operations are effective treatments for GERD. Despite standardized surgical techniques, variability in post-operative outcomes persists. Most patients with GERD possess one or more characteristics that augment their disease and may affect post-operative outcomes-a GERD "phenotype". We sought to define these phenotypes and to compare their post-operative outcomes.
METHODS: We performed a retrospective review of a prospective gastroesophageal database at our institution, selecting all patients who underwent an anti-reflux procedure for GERD. Patients were grouped into different phenotypes based on the presence of four characteristics known to play a role in GERD: hiatal or paraesophageal hernia (PEH), hypotensive LES, esophageal dysmotility, delayed gastric emptying (DGE), and obesity. Patient-reported outcomes (GERD-HRQL, dysphagia, and reflux symptom index (RSI) scores) were compared across phenotypes using the Wilcoxon rank-sum test.
RESULTS: 690 patients underwent an anti-reflux procedure between 2008 and 2022. Most patients underwent a Nissen fundoplication (302, 54%), followed by a Toupet or Dor fundoplication (205, 37%). Twelve distinct phenotypes emerged. Non-obese patients with normal esophageal motility, normotensive LES, no DGE, with a PEH represented the most common phenotype (134, 24%). The phenotype with the best post-operative GERD-HRQL scores at one year was defined by obesity, hypotensive LES, and PEH, while the phenotype with the worst scores was defined by obesity, ineffective motility, and PEH (1.5 ± 2.4 vs 9.8 ± 11.4, p = 0.010). There was no statistically significant difference in GERD-HRQL, dysphagia, or RSI scores between phenotypes after five years.
CONCLUSIONS: We have identified distinct phenotypes based on common GERD-associated patient characteristics. With further study these phenotypes may aid surgeons in prognosticating outcomes to individual patients considering an anti-reflux procedure.
We propose a 3-year study to develop and pilot test a social network substance use and HIV-risk intervention for permanent supportive housing program residents in the Skid Row area of Los Angeles. The intervention will be developed for residents at the Skid Row Housing Trust (SRHT), one of the largest Housing First providers in Los Angeles. Housing First residents are not required to abstain from alcohol and drugs as a requirement of their residency. There is some evidence that providing housing rapidly to chronically homeless persons--along with support--helps to reduce substance use and HIV risk behaviors in the short term because homelessness is the primary cause of high-risk behavior. However, the evidence thus far is limited. One aspect that has not received much research attention is the needs of Housing First residents for support to transition their social networks while transitioning out of homeless into residency in a Housing First program. New residents are exposed to a wide range of potentially negative social influences while also having greater potential to reconnect with lost positive ties. This project will develop a social network intervention to residents of SRHT in order to increase their knowledge about their social networks and enhance their motivation to make necessary changes to improve their ability to reduce or continue to abstain from high-risk behavior. The intervention sessions will enhance the weekly support meetings that SRHT case workers already conduct with new residents during their first 6 months of residency. Case workers will be trained to deliver the 30-minute intervention sessions using a motivational interviewing style. The intervention will be developed so that case managers can deliver it with the aid of an electronic tablet device. The tablet will guide them in collecting information about the residents' social networks and then display several diagrams highlighting various aspects of the residents' networks. They will then use motivational interviewing techniques to guide residents to think about how their network currently functions, how they would like it to function, and what steps they can take to make changes necessary to achieve goals related to reducing their substance use and sexual risk behaviors. The intervention will be delivered by case managers across four sessions (at baseline and at two-week intervals). We anticipate that residents who participate in this intervention will develop new strategies in their interactions with their social networks that will facilitate a reduction in their high-risk behavior.
Autism is a disorder characterized by social deficits, and among others by changes in communication. The diagnosis of this disorder remains accomplished by direct assessment the individual's behavior, according to specific clinical criteria present the classification systems of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Therapists teach autistic to communicate with the help of symbols and auxiliary anticipation and communication routines, usually using the Picture Exchange Communication System (PECS), or photos. However these are presented in transition PECS cards and do not follow the children in activities that develop outside the school environment. The objective of this work is to develop an application to run on a mobile device Android tablet that features the visual routines.

In this way the routines can be accessed outside the school environment. This technology is easy to use and facilitates data entry by touching the screen, was developed using the Unified Modeling Language (UML), Javascript, Apache Web server and Web browser Chrome. The application validation, will be held with 10 autistic and 2 teachers from the center of inclusion and support for autistic. Teachers should insert the activities programmed for each autistic student. Tablet in student performance in communicating with this tablet will be measured. Parents or guardians knowledge with the PECS system will be trained and will be evaluated on their autonomy inserting images, audio and subtitles. The application should aid communication, cause the autistic understand the sequence of events in daily life, decreasing their aggression because of not knowing what will be their next activity. Participation in this research poses no risk or harm the concerned person. If during the research participant decides not anymore have the freedom to do so without incurring any damage you. The technical validation proposal is necessary for it to be used by people with autism. If validated in a positive way, the technique could improve the quality of life of these people and their families.